Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

The passing of NHL great Pat Quinn Sunday night has brought back into focus his famous on-ice run-in with Boston Bruins icon Bobby Orr. And in this interview Quinn gave, he describes his view on ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Following a 10-win season, five Broncos have earned Associated Press All-Pro honors. Cornerback Pat Surtain II, right guard Quinn Meinerz and punt returner Marvin Mims Jr. were awarded first-team ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.